Takes the reader on a journey through the development of a treatment regimen for multiple myeloma called 'dtZ'. This book presents an account of how more than 50 patients with myeloma were given a non-toxic, precisely-targeted, anti-cancer treatment that was specifically adapted to their individual cancers.
Diagnostic Dilemmas; Shortcomings of Modern-Day Clinical Trials; Individualizing Core Parameters; Patient Compliance; Multiple Myeloma; Current Treatment; Future Opportunities.